Vol 7, No 2 (2006)

Table of Contents

Editorial

The breakthrough of public pharmaceutical expenditure in 2005
Mario Eandi
PDF PDF
87-88

Review (Economic Analysis)

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects
Carlo Lazzaro
PDF
89-96
Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer
Mario Eandi
PDF
97-117
Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs
Giorgio Mariani, Luca Guidi, Angelomarco Barioglio
PDF
119-124

Original research

Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico
Gianluca Falcitelli, Giuseppe Armentano, Corrado Pugliesi, Patrizio Tatti, Antonio Cimino
PDF
125-134